ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Natural Killer Cells"

  • Abstract Number: 1705 • ACR Convergence 2024

    Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome

    Paul Breillat1, Carbone Francesco2, Possémé Céline3, Marie Templé4, Aurélien Corneau5, Marine Luka2, Camille Gobeaux6, Rodéreau Outh7, Estibaliz Lazaro8, Guillaume Le Guenno9, François Lifermann10, Marie Berleur11, Melchior Le Mene4, Chloé Friedrich4, Cédric Lenormand12, Thierry Weitten13, Vivien Guillotin14, Barbara Burroni6, Jeremy Boussier15, Lise Willems6, Léa Dionet16, Tharaux Pierre-Louis16, Darragh duffy17, Mickael Ménager18, Olivier Kosmider4 and Benjamin Terrier19, 1Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM U970, Université de Paris, PARIS, France, 2Institut Imagine, Paris, France,, Paris, France, 3Institut Pasteur, Paris, France, Paris, France, 4Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France, Paris, France, 5Sorbonne Université, Paris, France, 6Cochin Hospital, Paris, France, Paris, France, 7CH, Perpignan, France,, Perpignan, France, 8Bordeaux University Hospital, Pessac, France, 9CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, 10Dax Hospital, Dax, France, Dax, France, 11CHU Bichat, Paris France, Paris, France, 12CHRU, Strasbourg, France, Strasbourg, France, 13CHIGAS, Gap, France, Gap, France, 14CHU Bordeaux, Bordeaux, France, Bordeaux, France, 15Sorbonne University, Paris, France, 16Paris Cardiovascular Research Center, INSERM U970, Paris, France, 17Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, 18Institut Imagine, Paris, France, Paris, France, 19Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a severe auto-inflammatory disorder associated with acquired mutations in the UBA1 gene that occur in hematopoietic stem cells…
  • Abstract Number: 1763 • ACR Convergence 2024

    Circulating NK and CD8+ Cytotoxic T Cells in Treatment Naïve JDM Demonstrate Higher Cytotoxic and Interferon Signature as Compared to Childhood-Onset SLE

    Qinmengge Li1, Celine Berthier1, Christine Goudsmit1, Sophia Matossian1, Rachael Wasikowski2, Johann Gudjonsson1, J. Michelle Kahlenberg1, Lam C. Tsoi2 and Jessica Turnier3, 1University of Michigan, Ann Arbor, MI, 2Michigan, Dept. of Dermatology, Ann Arbor, MI, 3University of Michigan, Saline, MI

    Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset systemic lupus erythematosus (cSLE) are pediatric autoimmune diseases that can present with overlapping clinical features yet have unique tropism…
  • Abstract Number: 1782 • ACR Convergence 2024

    DOCK2 Mutations and Hyper-Inflammatory Syndromes

    Randy Cron, Mingce Zhang and Prescott Atkinson, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal hyper-inflammatory complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous…
  • Abstract Number: 1786 • ACR Convergence 2024

    Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine

    Christian Wright1, Rufei Lu2, Catriona Wagner3, Carla Guthridge4, Susan Macwana1, Eliza Chakravarty4, Tammy Utset5, Diane Kamen6, Gabriel Nicolas Contreras Martin7, William McCune8, Cynthia Aranow9, Kenneth Kalunian10, Elena Massarotti11, Megan Clowse12, Brad Rovin13, S. Sam Lim14, Vikas Majithia15, Richard Looney16, Maria Dall'Era17, Doruk Erkan18, Amit Saxena19, Nancy Olsen20, Kichul Ko21, Ellen Goldmuntz22, William Barry23, Ashley Pinckney24, ALE06 Clinical Study Team4, Judith James4 and Joel Guthridge4, 1Oklahoma Medical Research Foundation, Oklahoma City, 2University of California San Francisco, San Bruno, CA, 3Oklahoma Medical Research Foundation, Santa Cruz, CA, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5University of Chicago, Chicago, IL, 6Medical University of South Carolina, Charleston, SC, 7University of Miami, Key Biscayne, FL, 8U Michigan, Ann Arbor, MI, 9Feinstein Institutes for Medical Research, New York, NY, 10University of California San Diego, La Jolla, CA, 11Brigham and Women's Hospital, Boston, MA, 12Duke University, Chapel Hill, NC, 13The Ohio State University, Columbus, OH, 14Emory University, Atlanta, GA, 15Mayo Clinic Florida, Jacksonville, FL, 16University of Rochester, Rochester, NY, 17UCSF, Corte Madera, CA, 18Hospital for Special Surgery, New York, NY, 19NYU School of Medicine, New York, NY, 20Penn State University/Milton S Hershey, Hershey, PA, 21The University of Chicago, Chicago, IL, 22NIAID/ NIH, Washington, DC, 23Rho, Inc, Durham, NC, 24Rho, St Louis Park, NC

    Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
  • Abstract Number: 2422 • ACR Convergence 2024

    Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy

    Anil Bagri1, Alec Witty1, Amanda Sims1, Allan Williams1, Rina Mbofung1, Daniel Morales-Mantilla1, Yang Wang1, Stacey Moreno1, Allison Aguilar1, Cara Bickers1, Yijia Pan1, Amber Chang1, Christine Chen1, Karina Palomares1, Lauren Fong1, Nicholas Brookhouser1, Berhan Mandefro1, Sajid Mahmood1, Ramesh Janani1, Ramzey Abujarour1, Tom Lee1, Raedun Clarke1, Rebecca Elstrom1, Frank Cichocki2, Lilly Wong1, Betsy Rezner1, Jode Goodridge1, Jeffrey Miller2 and Bahram Valamehr1, 1Fate Therapeutics Inc., San Diego, CA, 2Department of Medicine, University of Minnesota, Minneapolis, MN

    Background/Purpose: Unprecedented clinical data have recently shown that patients with certain highly refractory autoimmune diseases (AI Dz) treated with conditioning chemotherapy (CCT) and autologous anti-CD19…
  • Abstract Number: 0059 • ACR Convergence 2023

    GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice

    Can Sungur1, Li-ping Yang2, Liang Shan1 and wayne Yokoyama3, 1Washington University, St. Louis, MO, 2Washington University in St. Louis, St. Louis, MO, 3Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Human immunodeficiency virus (HIV) remains a significant life-threatening agent and burden on public health. Lesser studied and understood aspects of HIV include HIV-associated inflammatory…
  • Abstract Number: 1783 • ACR Convergence 2023

    Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis

    Marcos Chiñas1, Daniela Fernandez-Salinas1, Vitor Aguiar1, Victor Caballero-Nieto2, Micah Lefton3, Joerg Ermann4 and Maria Gutierrez-Arcelus1, 1Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Montpellier, France, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not…
  • Abstract Number: 0163 • ACR Convergence 2022

    Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic

    Christopher Costin1, Gabrielle Morgan2, Amer Khojah3 and Lauren Pachman4, 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Umm Al-Qura University, Makkah, Saudi Arabia, 4Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL

    Background/Purpose: Prior research has shown that viruses may trigger JDM, although the degree to which COVID-19 may serve as a trigger for JDM remains unknown.…
  • Abstract Number: 0288 • ACR Convergence 2022

    Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study

    Loïc Meudec1, Pauline Richebé1, Juliette Pascaud2, Xavier Mariette3 and Gaetane Nocturne4, 1Université Paris-Saclay, AP-HP-Hôpital Bicêtre, Le Kremlin Bicêtre, France, 2Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, 3Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 4APHP, Le Kremlin Bicêtre, France

    Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…
  • Abstract Number: 0612 • ACR Convergence 2022

    Peripheral Blood and Synovial Fluid Natural Killer (NK) and Natural Killer T (NKT) Cell Immunophenotypes in Active Rheumatoid Arthritis and Their Role as Biomarkers of Methotrexate Response

    Siddharth Jain1, Bidya Laishangtham1, Aastha Khullar1, Biman Saikia1 and Varun Dhir2, 1Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER, CHD, INDIA, Chandigarh, India

    Background/Purpose: It is still unclear whether Natural Killer (NK) and Natural Killer T (NKT) cells play a pathogenic or protective role in Rheumatoid Arthritis (RA).…
  • Abstract Number: 0629 • ACR Convergence 2022

    The Cellular Metabolism of SLE NK Cells Is Primarily Altered at the Level of Mitochondrial Respiration

    Natalia Fluder, Morgane Humbel, camillo Ribi and Denis Comte, Service of Immunology and Allergy / CHUV, Lausanne, Switzerland

    Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic inflammatory disorder, which involves a loss of tolerance and development of autoantibodies. The role of Natural Killer…
  • Abstract Number: 1175 • ACR Convergence 2022

    Epigenetic Regulation of MicroRNA-126 in Scleroderma Is Associated with Upregulation of DNA Methyltransferase-1, Repression of Endothelial Nitric Oxide Synthase Expression, and Enhanced Platelet Adhesion to Endothelial Cells

    Yongqing Wang and bashar Kahaleh, University of Toledo, Toledo, OH

    Background/Purpose: SSc vasculopathy is characterized by endothelial injury and deficient endothelial-dependent vasodilation leading to occlusive and proliferative vascular outcomes. Platelet activation and elevated circulating platelet…
  • Abstract Number: 1560 • ACR Convergence 2022

    Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease

    Martina Bonacini1, Francesco Muratore1, Giovanna Restuccia2, Laura Albertazzi2, Piera Zaldini2, Luca Cimino3, Rossana Colla2, Alessandro Zerbini1, Carlo Salvarani4 and Stefania Croci1, 1Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 2Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Behçet disease (BD) is an inflammatory chronic disease characterized by alternation of active and inactive phases. Steroids, Colchine, Azathioprine (Aza) and interferon α are…
  • Abstract Number: 1702 • ACR Convergence 2022

    Targeting CD6-CD318 Axis with UMCD6 (anti-CD6) Enhances in Vivo Killing of Cancer Cells Through Direct Activation of NK Cells

    Mikel Gurrea-Rubio1, Qi Wu1, Eliza Pei-Suen Tsou1, M. Asif Amin1, Phillip Campbell1, Peggy Randon1, Matthew Lind1, Sarah Ory1, Camila Amarista1, Sirapa Vichaikul2, Jeffrey Ruth1, Feng Ling3 and David Fox1, 1University of Michigan, Ann Arbor, MI, 2Michigan Medicine, Howell, MI, 3Cleveland Clinic, Cleveland, OH

    Background/Purpose: Immune checkpoint inhibitors represent a major advance in cancer treatment, but disease prognosis continues to be poor for most patients. Resistance of cancer cells…
  • Abstract Number: 1703 • ACR Convergence 2022

    Potential Regulation of NK Cells by CD1c+ Dendritic Cells Through RIG-I/DDX60 Pathway Involved in Th17 Responses in Primary Sjögren Syndrome

    Ildefonso Sánchez Cerrillo1, Marta Calvet Mirabent1, Ana Triguero2, Diego Calzada Fraile3, Mariel Valdivia1, Marta Ramírez3, Enrique Vázquez de Luis3, Alberto Benguría Filippini3, Roberto Moreno3, María Magdalena Adrados de llano1, Hortensia de la Fuente1, Ilya Tsukalov4, Emilia Roy Vallejo5, Almudena Ramiro3, Salvador Iborra6, Francisco Sánchez Madrid1, Ana Dopazo3, Isidoro Gonzalez7, Santos Castañeda8 and Enrique Martín Gayo4, 1Hospital La Princesa, Madrid, Spain, 2Hospital Universitario La Princesa, Madrid, Spain, 3Centro de Investigaciones Cardiovasculares, Madrid, Spain, 4Universidad Autónoma de Madrid, Madrid, Spain, 5Internal Medicine Department, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain, 6Universidad Complutense de Madrid, Madrid, Spain, 7Hospital Universitario de La Princesa, Madrid, Spain, 8Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain

    Background/Purpose: Altered Th17, CD8+ T cell and B cell adaptative immune responses in patients with primary Sjögren syndrome (pSS) have been characterized in salivary glands…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology